Skip to main content
NVDA-2.33%AAPL+3.12%GOOGL+0.37%MSFT+0.13%AMZN-0.10%TSM-1.05%SPCX+2.07%AVGO-0.48%META-0.84%TSLA-0.44%SKHY-3.77%MU-4.62%BRK-B-0.27%LLY+0.45%JPM-0.57%WMT+0.03%AMD-3.08%V-0.15%XOM+0.59%ASMLa-1.66%JNJ-0.10%INTC-4.85%MA-0.51%0700.HK-1.94%1398.HK+0.79%ORCL-3.65%ABBV+0.51%BAC-0.55%CSCO-1.25%CVX-0.29%COST-0.30%KO+0.61%LRCX-4.70%CAT-1.57%AP2d-1.55%0005.HK-0.78%AMAT-2.38%UNH-0.62%HSBA.L-1.30%DELL-3.68%PG+0.23%MS-0.91%GE-0.69%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.58%0939.HK+1.66%GS-0.91%NZDJPY-2.56%AUDJPY-1.81%CHFJPY-1.60%NZDCAD-1.40%EURNZD+1.40%GBPNZD+1.36%NZDUSD-1.31%USDJPY-1.29%GBPJPY-1.22%EURJPY-1.22%CADJPY-1.18%NZDCHF-1.00%USDZAR+0.93%USDNOK+0.84%EURZAR+0.83%USDSEK+0.82%AUDNZD+0.78%GBPZAR+0.76%EURNOK+0.74%EURSEK+0.71%AUDCAD-0.66%AUDDKK-0.63%EURAUD+0.61%GBPAUD+0.58%CHFNOK+0.57%USDTHB+0.56%CHFSEK+0.55%AUDUSD-0.54%AUDSGD-0.51%USDMXN+0.43%GBPTRY+0.41%CADCHF+0.40%NOKJPY-0.39%EURCHF+0.38%GBPCHF+0.36%NZDSGD-0.36%USDPLN+0.35%USDCHF+0.32%GBPHKD+0.32%GBPMXN-0.28%EURPLN+0.25%SGDJPY+0.23%USDSGD+0.22%AUDCHF-0.22%NZDMXN-0.17%USDILS+0.16%EURSGD+0.12%EURHKD-0.11%USDTRY+0.11%PLNJPY+0.11%USDDKK+0.11%AUDNOK+0.10%USDCAD-0.09%EURCZK-0.09%USDCNH+0.09%EURUSD+0.06%GBPUSD+0.06%GBPCAD-0.05%GBPSGD+0.05%CHFSGD-0.04%USDCOP-0.04%EURCAD-0.03%EURGBP+0.02%USDHKD+0.01%EURCNH0.00%EURDKK0.00%XPTUSD-5.60%UKOIL+5.27%USOIL+4.94%HG1-4.78%GAGUSD-4.56%XAGUSD-4.56%GAUUSD-1.03%XAUUSD-1.03%XNGUSD+0.99%COTTON+0.72%S1+0.67%W1+0.56%BTCUSD-1.18%ETHUSD+0.03%USDTUSD-0.03%XRPUSD-2.45%SOLUSD-1.45%TRXUSDT+0.24%ZECUSDT-7.22%DOGEUSD-2.57%XMRUSDT-0.30%LINKUSD-0.93%XLMUSD-1.29%BCHUSDT-9.87%LTCUSD-1.49%UNIUSD-1.22%TONUSD+24.88%HBARUSDT-2.14%SUIUSD-3.57%TAOUSDT-4.58%AAVEUSD-2.14%DOTUSDT-1.20%ICPUSDT-1.26%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.03%ARBUSDT+0.12%JUPUSDT-3.82%INJUSDT-2.63%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-0.60%PYTHUSDT-0.94%SEIUSDT-6.02%IMXUSDT-3.06%GRTUSDT-2.81%WIFUSDT-4.89%OPUSDT-3.00%POLUSDT-4.28%IOTAUSDT-3.30%AXSUSDT-2.04%FARTCOINUSDT-3.53%EOSUSDT-2.41%DYDXUSDT-1.85%ORDIUSDT-0.60%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.33%AAPL+3.12%GOOGL+0.37%MSFT+0.13%AMZN-0.10%TSM-1.05%SPCX+2.07%AVGO-0.48%META-0.84%TSLA-0.44%SKHY-3.77%MU-4.62%BRK-B-0.27%LLY+0.45%JPM-0.57%WMT+0.03%AMD-3.08%V-0.15%XOM+0.59%ASMLa-1.66%JNJ-0.10%INTC-4.85%MA-0.51%0700.HK-1.94%1398.HK+0.79%ORCL-3.65%ABBV+0.51%BAC-0.55%CSCO-1.25%CVX-0.29%COST-0.30%KO+0.61%LRCX-4.70%CAT-1.57%AP2d-1.55%0005.HK-0.78%AMAT-2.38%UNH-0.62%HSBA.L-1.30%DELL-3.68%PG+0.23%MS-0.91%GE-0.69%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.58%0939.HK+1.66%GS-0.91%NZDJPY-2.56%AUDJPY-1.81%CHFJPY-1.60%NZDCAD-1.40%EURNZD+1.40%GBPNZD+1.36%NZDUSD-1.31%USDJPY-1.29%GBPJPY-1.22%EURJPY-1.22%CADJPY-1.18%NZDCHF-1.00%USDZAR+0.93%USDNOK+0.84%EURZAR+0.83%USDSEK+0.82%AUDNZD+0.78%GBPZAR+0.76%EURNOK+0.74%EURSEK+0.71%AUDCAD-0.66%AUDDKK-0.63%EURAUD+0.61%GBPAUD+0.58%CHFNOK+0.57%USDTHB+0.56%CHFSEK+0.55%AUDUSD-0.54%AUDSGD-0.51%USDMXN+0.43%GBPTRY+0.41%CADCHF+0.40%NOKJPY-0.39%EURCHF+0.38%GBPCHF+0.36%NZDSGD-0.36%USDPLN+0.35%USDCHF+0.32%GBPHKD+0.32%GBPMXN-0.28%EURPLN+0.25%SGDJPY+0.23%USDSGD+0.22%AUDCHF-0.22%NZDMXN-0.17%USDILS+0.16%EURSGD+0.12%EURHKD-0.11%USDTRY+0.11%PLNJPY+0.11%USDDKK+0.11%AUDNOK+0.10%USDCAD-0.09%EURCZK-0.09%USDCNH+0.09%EURUSD+0.06%GBPUSD+0.06%GBPCAD-0.05%GBPSGD+0.05%CHFSGD-0.04%USDCOP-0.04%EURCAD-0.03%EURGBP+0.02%USDHKD+0.01%EURCNH0.00%EURDKK0.00%XPTUSD-5.60%UKOIL+5.27%USOIL+4.94%HG1-4.78%GAGUSD-4.56%XAGUSD-4.56%GAUUSD-1.03%XAUUSD-1.03%XNGUSD+0.99%COTTON+0.72%S1+0.67%W1+0.56%BTCUSD-1.18%ETHUSD+0.03%USDTUSD-0.03%XRPUSD-2.45%SOLUSD-1.45%TRXUSDT+0.24%ZECUSDT-7.22%DOGEUSD-2.57%XMRUSDT-0.30%LINKUSD-0.93%XLMUSD-1.29%BCHUSDT-9.87%LTCUSD-1.49%UNIUSD-1.22%TONUSD+24.88%HBARUSDT-2.14%SUIUSD-3.57%TAOUSDT-4.58%AAVEUSD-2.14%DOTUSDT-1.20%ICPUSDT-1.26%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.03%ARBUSDT+0.12%JUPUSDT-3.82%INJUSDT-2.63%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-0.60%PYTHUSDT-0.94%SEIUSDT-6.02%IMXUSDT-3.06%GRTUSDT-2.81%WIFUSDT-4.89%OPUSDT-3.00%POLUSDT-4.28%IOTAUSDT-3.30%AXSUSDT-2.04%FARTCOINUSDT-3.53%EOSUSDT-2.41%DYDXUSDT-1.85%ORDIUSDT-0.60%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%
CO

Coherus Oncology, Inc. (CHRS)

NASDAQ • Healthcare

$1.32
-$0.05 (-3.6%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$1.34
Previous Close$1.32
Day Range$1.31 - $1.38
Avg. Volume (3M)1.1M
Market Cap$204.7M
52 Week Range
$1.09$2.62
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$14.3M100%
Gross Profitminus cost of goods$10M70%

Fundamentals & Financials

Revenue (TTM)
$50.9M
Net Income (TTM)
-$130.9M
EPS (TTM)
-$1.02
ROA (TTM)
-68.5%
Current Ratio
1.77

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+4.2%Q1 2026-$0.34
+5.1%Q2 2026-$0.25
+24.0%Q3 2026-$0.19
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a U.S. biotechnology company focused primarily on researching, developing, and commercializing cancer immunotherapies, while also marketing a small portfolio of biosimilar medicines in supportive care, immunology, and ophthalmology. Listed on NASDAQ as CHRS, it generated $42.2 million of revenue in FY2025.

Name
Coherus Oncology, Inc.
CEO
Dennis Lanfear
Website
www.coherus.com
Industry
Healthcare
Year Founded
2010
Employees
144

Today's Snapshot

AI-generated

So far today, CHRS is trading slightly higher at 1.32, in line with a flat sector.

Trading Volume

Below 10d avg (645.3K)

492.2K

vs S&P 500 Today

Outperforming Market

+0.77%

Updated: September 10, 2026 at 16:54 UTC

Technical Indicators

0 Buy2 Neutral6 Sell
CHRS is rated a strong sell as the price sits below most short-, medium- and long-term moving averages, undercutting the 200-day area and signaling a broad technical downshift. Momentum measures are negative and MACD is on the sell side, while ADX shows a weak directional backdrop so there is little trend support for rallies. Volatility is meaningful for the share price, with ATR reflecting a multi-percent move, and on-balance volume is one of the few constructive items, suggesting some accumulation but not enough to offset the other negatives. Technical takeaway: Strong Sell — below major averages with weak trend and negative momentum.
All signals
  • EMA (5 indicators)$1.36 - $1.52
    Sell
  • RSI (14)46.46
    Neutral
  • Stochastic %K (14, 3, 3)28.38
    Neutral
  • MACD Level (12, 26)-0.00
    Sell

Peers & Related Assets

SLSSELLAS Life Sciences Group, Inc.
$13.95-0.1%
OABIOmniAb, Inc.
$4.01-5.4%
CDXSCodexis, Inc.
$1.430.0%
AVTXAvalo Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
IVVDInvivyd, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.